Epigallocatechin Gallate Preferentially Inhibits O⁶-Methylguanine DNA-Methyltransferase Expression in Glioblastoma Cells Rather than in Nontumor Glial Cells

References

• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987–996, 2005.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997–1003, 2005.
   PubMed Web of Science ®Google Scholar
• Dahlrot RH, Dowsett J, Fosmark S, Malmstrom A, Henriksson R, et al.: Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. Neuropathol Appl Neurobiol 44, 172–184, 2017.
   PubMed Web of Science ®Google Scholar
• Ramalho-Carvalho J, Pires M, Lisboa S, Graca I, Rocha P, et al.: Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations. PLoS One 8, e58206, 2013.
   PubMed Web of Science ®Google Scholar
• Wick W, Weller M, van den Bent M, Sanson M, Weiler M, et al.: MGMT testing-the challenges for biomarker-based glioma treatment. Nat Rev Neurol 10, 372–385, 2014.
   PubMed Web of Science ®Google Scholar
• Yang CS, Maliakal P, and Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42, 25–54, 2002.
   PubMed Web of Science ®Google Scholar
• Clark J and You M: Chemoprevention of lung cancer by tea. Mol Nutr Food Res 50, 144–151, 2006.
   PubMed Web of Science ®Google Scholar
• Hou Z, Lambert JD, Chin KV, and Yang CS: Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. Mutat Res 555, 3–19, 2004.
   PubMed Web of Science ®Google Scholar
• Balentine DA, Wiseman SA, and Bouwens LC: The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37, 693–704, 1997.
   PubMed Web of Science ®Google Scholar
• Valcic S, Burr JA, Timmermann BN, and Liebler DC: Antioxidant chemistry of green tea catechins. New oxidation products of (−)-epigallocatechin gallate and (−)-epigallocatechin from their reactions with peroxyl radicals. Chem Res Toxicol 13, 801–810, 2000.
   PubMed Web of Science ®Google Scholar
• Farabegoli F, Papi A, Bartolini G, Ostan R, and Orlandi M: (−)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 17, 356–362, 2010.
   PubMed Web of Science ®Google Scholar
• Shankar S, Ganapathy S, and Srivastava RK: Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci 12, 4881–4899, 2007.
   PubMed Web of Science ®Google Scholar
• Singh BN, Shankar S, and Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82, 1807–1821, 2011.
   PubMed Web of Science ®Google Scholar
• Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, et al.: Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63, 7563–7570, 2003.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Hainfellner JA, Marosi C, and Preusser M: Assessing MGMT methylation status and its current impact on treatment in glioblastoma. CNS Oncol 4, 47–52, 2015.
   PubMedGoogle Scholar
• Wickstrom M, Dyberg C, Milosevic J, Einvik C, Calero R, et al.: Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun 6, 8904, 2015.
   PubMed Web of Science ®Google Scholar
• Fu D, Calvo JA, and Samson LD: Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 12, 104–120, 2012.
   PubMed Web of Science ®Google Scholar
• Belanich M, Randall T, Pastor MA, Kibitel JT, Alas LG, et al.: Intracellular localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol 37, 547–555, 1996.
   PubMed Web of Science ®Google Scholar
• Shirai K and Chakravarti A: Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther 11, 1935–1944, 2011.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, et al.: Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31, 4085–4091, 2013.
   PubMed Web of Science ®Google Scholar
• Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, et al.: Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol 17, 266–273, 2015.
   PubMed Web of Science ®Google Scholar
• Nagane M: Dose-dense temozolomide: is it still promising? Neurol Med Chir (Tokyo) 55, 38–49, 2015.
   Web of Science ®Google Scholar
• Kreklau EL, Liu N, Li Z, Cornetta K, and Erickson LC: Comparison of single- versus double-bolus treatments of O(6)-benzylguanine for depletion of O(6)-methylguanine DNA methyltransferase (MGMT) activity in vivo: development of a novel fluorometric oligonucleotide assay for measurement of MGMT activity. J Pharmacol Exp Ther 297, 524–530, 2001.
   PubMed Web of Science ®Google Scholar
• Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, et al.: Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27, 1262–1267, 2009.
   PubMed Web of Science ®Google Scholar
• Chen ZP, Pan J, Huang Q, Sun ZF, Zhou LY, et al.: Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter. Chin J Cancer Res 12, 1, 2000.
   Google Scholar
• Huang H, Lin H, Zhang X, and Li J: Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway. Oncol Rep 27, 2050–2056, 2012.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, et al.: Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med 52, 377–391, 2012.
   PubMed Web of Science ®Google Scholar
• Paranjpe A, Zhang R, Ali-Osman F, Bobustuc GC, and Srivenugopal KS: Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis 35, 692–702, 2014.
   PubMed Web of Science ®Google Scholar
• Le CT, Leenders WPJ, Molenaar RJ, and van Noorden CJF: Effects of the green tea polyphenol epigallocatechin-3-gallate on glioma: a critical evaluation of the literature. Nutr Cancer 70, 317–333, 2018.
   PubMed Web of Science ®Google Scholar
• Chen TC, Wang W, Golden EB, Thomas S, Sivakumar W, et al.: Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett 302, 100–108, 2011.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang SX, Ma JW, Li HY, Ye JC, et al.: EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. J Neurooncol 121, 41–52, 2015.
   PubMed Web of Science ®Google Scholar
• Zhang M, Herion TW, Timke C, Han N, Hauser K, et al.: Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia 13, 537–549, 2011.
   PubMed Web of Science ®Google Scholar
• Pervin M, Unno K, Nakagawa A, Takahashi Y, Iguchi K, et al.: Blood brain barrier permeability of (−)-epigallocatechin gallate, its proliferation-enhancing activity of human neuroblastoma SH-SY5Y cells, and its preventive effect on age-related cognitive dysfunction in mice. Biochem Biophys Rep 9, 180–186, 2017.
   PubMedGoogle Scholar